Abraxane
E932801
anticancer drug
chemotherapy agent
nanoparticle albumin-bound paclitaxel formulation
pharmaceutical drug
Abraxane is a nanoparticle albumin-bound formulation of the chemotherapy drug paclitaxel used to treat various cancers, including breast, lung, and pancreatic cancer.
Statements (49)
| Predicate | Object |
|---|---|
| instanceOf |
anticancer drug
ⓘ
chemotherapy agent ⓘ nanoparticle albumin-bound paclitaxel formulation ⓘ pharmaceutical drug ⓘ |
| approvedBy | U.S. Food and Drug Administration NERFINISHED ⓘ |
| containsExcipient | human serum albumin ⓘ |
| developedBy | Abraxis BioScience NERFINISHED ⓘ |
| doesNotContain | Cremophor EL NERFINISHED ⓘ |
| hasActiveIngredient | paclitaxel ⓘ |
| hasAdministrationSchedule | intermittent cycles ⓘ |
| hasATCCode | L01CD01 ⓘ |
| hasBrandName | Abraxane NERFINISHED ⓘ |
| hasCommonAdverseEffect |
alopecia
ⓘ
anemia ⓘ fatigue ⓘ nausea ⓘ neutropenia ⓘ peripheral neuropathy ⓘ |
| hasContraindication |
history of severe hypersensitivity to paclitaxel
ⓘ
severe neutropenia ⓘ |
| hasDosageForm | lyophilized powder for suspension for infusion ⓘ |
| hasDrugClass |
mitotic inhibitor
ⓘ
taxane ⓘ |
| hasFirstFDAApprovalYear | 2005 ⓘ |
| hasFormulation | albumin-bound nanoparticles ⓘ |
| hasGenericName | paclitaxel protein-bound particles for injectable suspension ⓘ |
| hasIndication |
locally advanced pancreatic cancer
ⓘ
metastatic breast cancer ⓘ metastatic pancreatic cancer ⓘ non-small cell lung cancer ⓘ |
| hasMechanismOfAction |
inhibits microtubule depolymerization
ⓘ
inhibits mitosis in cancer cells ⓘ stabilizes microtubules ⓘ |
| hasPregnancyCategory | embryo-fetal toxicity risk ⓘ |
| hasRegulatoryStatus | prescription-only medicine ⓘ |
| hasRouteOfAdministration | intravenous infusion ⓘ |
| hasSeriousAdverseEffect |
pneumonitis
ⓘ
sepsis ⓘ severe hypersensitivity reaction ⓘ severe neutropenia ⓘ |
| hasTargetProcess | cell division ⓘ |
| indicatedPopulation | adult patients ⓘ |
| isCytotoxic | true ⓘ |
| marketedBy | Bristol Myers Squibb NERFINISHED ⓘ |
| requiresMonitoring |
complete blood counts
ⓘ
liver function tests ⓘ |
| requiresPremedication | not routinely required with steroids and antihistamines ⓘ |
| usedInCombinationWith |
carboplatin
NERFINISHED
ⓘ
gemcitabine ⓘ |
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.